Ventricular tachycardia
Conditions
Interventions
The pro-arrhythmic cardiac region is identified by combining anatomical imaging with non-invasive body surface potential mapping during VT induction with non-invasive programmed stimulation. Radiother
Sponsors
Amsterdam University Medical Centers
Eligibility
Inclusion criteria
Inclusion criteria: 1 Age >18 years 2 Implanted ICD 3 World Health Organization (WHO) / Eastern Cooperative Oncology Group (ECOG) performance status grade 0-3 in the past 3 months (from fully active to capable of limited self-care, see below for full explanation) 4 At least 3 episodes of treated VT within the last 3 months 5 Recurrence of VT after -Failed or intolerant to least one class 1 or class 3 anti-arrhythmic drug AND -At least one catheter ablation procedure OR considered to be unsuitable for a catheter ablation procedure (e.g. no sufficient vascular access, considered unfit to undergo prolonged general anesthesia, comorbid conditions resulting in unacceptable peri-procedural risks) 6 Able and willing to undergo all necessary evaluations, treatment and follow-up for the study and of follow-up thereafter 7 Informed consent
Exclusion criteria
Exclusion criteria: 1 Pregnancy 2 History of radiation treatment in the thorax or upper abdominal region 3 Interstitial pulmonary disease 4 Renal insufficiency with a glomerular filtration rate <30ml/min 5 Refusal or inability to provide informed consent or to undergo all necessary evaluations, treatment and follow-up for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main efficacy measure is a reduction in the number of ICD treated VT episodes by =50% at one year after treatment compared to the year before treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measure is a =50% reduction in daily dose class 1 and 3 anti-arrhythmic drugs at one year after treatment as compared to baseline | — |
Contacts
Public ContactP.G. Postema
Amsterdam UMC, location AMC
Outcome results
None listed